Hubei Biocause Heilen Pharmaceutical Co. Ltd. Net Asset Quality Index
Hubei Biocause Heilen Pharmaceutical Co. Ltd. net asset quality index. Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Net Asset Quality Index of 95.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.40 Billion minus total liabilities of CN¥117.63 Million yields net assets of CN¥2.28 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 301211 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
Net asset quality index of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025. This chart shows how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s Net Asset Quality Index has evolved across 9 annual periods from 2017 to 2025. As of March 2026, the index stands at 95.1%, representing net assets of CN¥2.28 Billion against total assets of CN¥2.40 Billion CNY. See Hubei Biocause Heilen Pharmaceutical Co. (301211) shareholders funds for net asset value and shareholders' equity analysis.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Net Asset Quality Index by Year (2017–2025)
Hubei Biocause Heilen Pharmaceutical Co. Ltd. net asset quality index by year from 2017 to 2025. The table below presents the year-by-year Net Asset Quality Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025, covering 9 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see how much is Hubei Biocause Heilen Pharmaceutical Co. worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 94.6% | CN¥2.27 Billion | CN¥2.40 Billion | CN¥128.65 Million | ▲ +1.8 pp |
| 2024 | 92.8% | CN¥2.31 Billion | CN¥2.49 Billion | CN¥178.97 Million | ▲ +0.3 pp |
| 2023 | 92.5% | CN¥2.36 Billion | CN¥2.55 Billion | CN¥189.89 Million | ▲ +1.4 pp |
| 2022 | 91.1% | CN¥2.28 Billion | CN¥2.50 Billion | CN¥221.22 Million | ▼ -4.2 pp |
| 2021 | 95.4% | CN¥2.22 Billion | CN¥2.33 Billion | CN¥107.53 Million | ▲ +8.2 pp |
| 2020 | 87.2% | CN¥700.39 Million | CN¥803.25 Million | CN¥102.85 Million | ▲ +21.7 pp |
| 2019 | 65.5% | CN¥488.25 Million | CN¥745.56 Million | CN¥257.31 Million | ▲ +3.0 pp |
| 2018 | 62.5% | CN¥399.87 Million | CN¥640.24 Million | CN¥240.36 Million | ▲ +4.9 pp |
| 2017 | 57.5% | CN¥307.65 Million | CN¥534.90 Million | CN¥227.25 Million | — |